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Thrombosis is a common, life-threatening consequence of systemic infection; however, the
underlying mechanisms that drive the formation of infection-associated thrombi are poorly
understood. Here, using a mouse model of systemic Salmonella Typhimurium infection, we
determined that inflammation in tissues triggers thrombosis within vessels via ligation of C-
type lectin–like receptor-2 (CLEC-2) on platelets by podoplanin exposed to the vasculature
following breaching of the vessel wall. During infection, mice developed thrombi that
persisted for weeks within the liver. Bacteria triggered but did not maintain this process, as
thrombosis peaked at times when bacteremia was absent and bacteria in tissues were
reduced by more than 90% from their peak levels. Thrombus development was triggered by
an innate, TLR4-dependent inflammatory cascade that was independent of classical
glycoprotein VI–mediated (GPVI-mediated) platelet activation. After infection, IFN-g release
enhanced the number of podoplanin-expressing monocytes and Kupffer cells in the hepatic
parenchyma and perivascular sites and absence of TLR4, IFN-g, or depletion of monocytic-
lineage cells or CLEC-2 on platelets markedly inhibited the process. Together, our data
indicate that infection-driven thrombosis follows local inflammation and upregulation of
podoplanin and platelet activation. The identification of this pathway offers potential
therapeutic opportunities to control the devastating consequences of infection-driven
thrombosis without increasing the risk of bleeding.
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Introduction
Thrombosis-associated events are among the leading causes 
of death worldwide. Systemic infections caused by a plethora of 
bacterial genera can initiate thrombus development. While the 
mechanisms that underlie this process during some infections, 
particularly for Gram-positive organisms such as staphylococci 
or streptococci, have been described, these mechanisms are not 
universally applicable. This is illustrated by the limited efficacy of 
current treatments to modulate thrombosis during infection.
In typhoid, a systemic infection caused by Salmonella Typhi, 
bacteria colonize sites such as the spleen and liver, where they 
reside within monocytes and macrophages (1, 2). This systemic 
spread of infection causes a modest bacteremia, typically with less 
than 10 bacteria per ml of blood, and a widespread inflammatory 
response (3, 4). The infection is limited by the innate immune sys-
tem, but control and clearance of the bacteria require an adaptive 
Th1 response and induction of IFN-γ (5). Before the introduction 
of antimicrobial treatments for typhoid, thrombosis was com-
monly described as a complication of this infection that could 
result in death; reports have noted a relationship between typhoid 
and thrombosis for over a century (6–8). Thrombosis is also seen 
in mouse models of typhoid caused by Salmonella Typhimurium, 
suggesting that this consequence of systemic infection is con-
served in multiple species (9). Susceptibility of mice to Salmonella 
infections is strongly influenced by their expression of distinct 
versions of natural resistance-associated macrophage protein 1 
(NRAMP1, also known as SLC11A1) (10), which differ by a single 
amino acid. When mice that are innately more resistant to viru-
lent Salmonella are infected, thrombi can be seen in multiple sites 
throughout the body, including the spleen, liver, and kidneys (9, 
11). On the other hand, mice that, due to Nramp1, are hypersus-
ceptible to systemic infection with virulent S. Typhimurium, such 
as the commonly used laboratory strains C57BL/6J and BALB/c, 
succumb rapidly to this infection in just a few days. This adds a 
layer of complexity in mechanistic studies, since most genetically 
altered mice are of a C57BL/6J or BALB/c background. Neverthe-
less, many features of S. Typhimurium infection in resistant mice, 
including the modest bacteremia and thrombosis in the liver, can 
be reproduced in hypersusceptible mice using an attenuated strain 
of S. Typhimurium. In such experimentally infected mice, bacte-
rial numbers can be in the hundreds of thousands in sites such as 
the spleen and liver and yet be concurrently many thousand-fold 
lower in the blood before the infection resolves gradually over a 
period of weeks (12). Infection of resistant mice with virulent Sal-
monella or infection of hypersusceptible mice with attenuated Sal-
monella both commonly result in thrombosis (9, 13).
Recently, a beneficial role for thrombosis during inflammation 
has been described, whereby platelet aggregation and coagulation 
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(22). In the steady state, podoplanin has a restricted distribution 
outside the vasculature, with high levels on lymphatic endothelial 
cells, but is markedly upregulated on multiple cells, including mac-
rophages and Th17 cells, during inflammation (23, 24).
In this study, we investigate the molecular mechanism of 
thrombus development in the hepatic vasculature during systemic 
S. Typhimurium infection. We show that inflammation directly 
induces thrombosis and that these formerly distinct host responses 
are linked by podoplanin upregulation on macrophage subsets in 
the liver during infection. This results in an alternative pathway of in 
vivo platelet activation during inflammation, mediated by CLEC-2 
and its ligand, podoplanin. This distinct mechanism of platelet acti-
vation and thrombosis is independent of the major hemostatic path-
ways. This therefore identifies new opportunities for therapeutic 
interventions during inflammation-associated thrombosis that are 
likely to be unaffected by the deleterious bleeding complications 
associated with current antiplatelet strategies.
Results
Systemic S. Typhimurium infection induces thrombi formation 
within the hepatic vasculature. Administration i.p. of attenuated S. 
Typhimurium resulted in a systemic infection characterized by 
can contribute to bacterial containment and ultimately clearance 
within the vasculature at localized sites, a process termed immu-
nothrombosis (14). Indeed, some bacteria actively dissociate clots, 
enabling bacterial dissemination. For example, streptococci spe-
cies can dissolve fibrin via streptokinase-mediated plasmin acti-
vation (15). Additionally, neutrophil extracellular traps, which also 
contribute to bacterial containment within the vasculature, exhib-
it potent procoagulant features (16, 17). On the other hand, certain 
bacteria purposely activate coagulation as a method of immune 
evasion. For example, Staphylococcus aureus disguises itself within 
a fibrin-containing pseudocapsule formed via staphylocoagulase-
mediated prothrombin activation (18). Furthermore, direct inter-
action between bacteria and platelets, which may also contribute 
to the widely acknowledged ability of bacteria to manipulate the 
clotting system, has been described (19–21). Therefore, although 
bacteria can have a profound relationship with the clotting cas-
cade, the actual nature of this is variable and often complex.
Despite being the focus of much investigation, the link between 
the distinct pathways of inflammation and platelet activation is not 
yet fully understood. Platelets can be activated through multiple 
pathways, including by ligation of platelet-expressed C-type lectin–
like receptor-2 (CLEC-2) to its cognate ligand/receptor, podoplanin 
Figure 1. Inflammatory foci develop in the liver during S. Typhimurium infection. WT mice were infected i.p. with 5 × 105 CFU S. Typhimurium (STm). 
(A) Bacterial colonization 7 days after infection. (B) Bacterial colonization of the liver. (C) Number of leukocytes isolated from the liver. (D) Noninfected 
(NI) and day 7–infected serial liver sections stained by IHC for F4/80 (blue), CD3 (brown); and F4/80 (blue), CD11c (brown). Arrows indicate inflammatory 
lesions. (E) Serial sections of a lesion stained for F4/80 (blue), CD3 (brown); F4/80 (blue), CD11c (brown); Ly6C (blue), CD3 (brown); and Ly6G (blue), CD3 
(brown). (F) Fluorescent confocal microscopy image of day 7–infected liver stained for F4/80 (green) and CD11c (red). (G) Percentage area of liver occupied 
by inflammatory lesions quantified by point counting. Graphs show mean + SD. Data are representative of a minimum of 3 experiments, where n ≥ 4 mice 
in each group. Statistical significance (1-way ANOVA with Dunnett’s test) was determined relative to day 7 after infection (B) or relative to noninfected 
mice (C and G). ***P ≤ 0.001. Scale bars: 100 μm.
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the adjacent vessels of the portal triad) and were not detected in 
arterial vessels or sinusoids (Figure 2C). In addition, thrombi typi-
cally associated with perivasculature inflammatory infiltrates and 
were frequently surrounded by a peripheral cuff of leukocytes, 
suggesting thrombi formed in situ in the liver (Figure 2D). Throm-
bosis development was similar when bacteria were administered 
by either an i.p. or an i.v. route (Figure 2E). Despite the extensive 
accumulation of leukocytes and the development of thrombi, bio-
markers of liver injury showed limited changes; there was indica-
tion of some reversible injury, which returned to preinfection lev-
els by day 35 after infection (Figure 2, F–J).
Platelet thrombi develop in parallel with inflammatory lesions. 
Thrombi were white upon macroscopic inspection and were thus 
primarily composed of platelets, as confirmed using a platelet-
specific marker, the integrin subunit αIIb/CD41 (Figure 3, A and 
B). Thrombi were detectable by day 5 after infection and peaked 
in extent between days 7 and 21 (Figure 3C and data not shown). 
multiple sites of bacterial colonization, including spleen, liver, 
kidney, and lungs (Figure 1A). In the liver, bacterial load peaked 
within 7 days, and bacteria were largely cleared from this site 
after 1 month (Figure 1B). Infection induced the accumulation of 
leukocytes throughout the liver, which were organized in discrete 
inflammatory foci (Figure 1, C and D). Foci were primarily com-
posed of myeloid cells that express varying combinations of F4/80, 
CD11c, and Ly6C (primarily cells of the monocyte lineage) as well 
as a small number of CD3+ T lymphocytes, but few Ly6G+ neutro-
phils (Figure 1, E and F). Inflammatory foci were still present at 21 
days, when bacterial numbers were significantly reduced (Figure 
1G). Thus, the host inflammatory response to systemic infection 
persisted in the liver once bacterial clearance was established.
In addition to the development of inflammatory foci in the 
liver, S. Typhimurium infection induced extensive thrombosis 
within the liver vasculature (Figure 2, A and B). Thrombi formed 
predominantly within branches of the portal vein (as identified by 
Figure 2. Extensive thrombosis is a consequence of S. Typhimurium infection. WT mice were infected i.p. with S. Typhimurium as above. (A) H&E stain-
ing of paraffin-embedded sections from noninfected and day 7–infected liver. (B) Tile scan of H&E-stained frozen liver sections from noninfected and 
day 7–infected mice. (C) Thrombi are observed in the portal vein; 7 day–infected paraffin-embedded section. (D) IHC staining of frozen liver sections at 
day 7 after infection: CD3 (brown), F4/80 (blue); and CD11c (brown), F4/80 (blue). (E) WT mice were infected i.p. or i.v. as above for 7 days. Thrombosis was 
examined by H&E, and percentage of vessel occlusion was quantified in large vessels. (F–J) WT mice were infected i.p. as above, and enzymes associated 
with liver injury were measured in the serum throughout infection. Graphs show mean + SD. Data are representative of a minimum of 3 experiments, 
where n ≥ 4 mice in each group. Scale bars: 100 μm. V, blood vessel; T, thrombus; PV, portal vein; HA, hepatic artery; BD, bile duct; ALP, alkaline phospha-
tase; ALT, alanine aminotransferase; AST, aspartate aminotransferase.
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markers of increased platelet production, mean platelet volume 
and extramedullary megakaryocytopoiesis, parallel the kinetics of 
thrombosis severity.
Thrombus development is not altered by common antiplatelet agents. 
One prominent mechanism of initiation of platelet-driven thrombo-
sis is through activation of the platelet-specific collagen receptor gly-
coprotein VI (GPVI) (26). However, thrombus development during 
S. Typhimurium infection was not altered in mice deficient in GPVI, 
indicating that thrombosis must be regulated by an alternative path-
way that is specifically induced after exposure to bacteria (Figure 4, 
A and B). Furthermore, treatment of mice with the common anti-
platelet agent clopidogrel, which targets the platelet ADP receptor 
P2Y12, also had no effect on thrombus development, and neither did 
treatment with aspirin or heparin (Figure 4, C–F).
The observation that the dynamics of induction, maintenance, 
and resolution of thrombi parallel those of inflammatory lesions 
However, while the development of thrombi was infection mediat-
ed, the continued presence of thrombosis was not dependent upon 
a continuing bacteremia (Figure 3D). In addition to an absence of 
bacteremia beyond day 14, tissue bacterial loads were cleared to 
approximately 10% of their peak numbers by day 21, when vessel 
occlusion was still near its peak (Figure 1B and Figure 3C). Thus, S. 
Typhimurium induces thrombosis within the liver, but the main-
tenance of this thrombosis is not determined by the persistence of 
bacteria in the blood or in the tissues.
Thrombosis is mirrored by a severe thrombocytopenia, a find-
ing commonly observed with this infection (Figure 3E and ref. 9). 
Mean platelet volume and megakaryocyte numbers in the spleen, 
which are commonly associated with thrombocytopenia, were 
also increased, and the marker of accelerated platelet production, 
serum thrombopoietin, was increased during infection (Figure 3, 
F–I, and ref. 25). Thus, diminished platelet count and 2 indirect 
Figure 3. Infection is associated with altered platelet homeostasis. WT mice were infected i.p. as above. (A) Photomicrographs of noninfected and day 
7–infected frozen liver tissue. (B) Fluorescent confocal microscopy on frozen liver sections of noninfected and day 7–infected mice: CD41 (green), Hoechst 
(gray). Scale bars: 200 μm. (C) Vessel occlusion was quantified by point counting of large vessels per tissue section. Statistical significance of thrombosis 
resolution was determined relative to day 7 after infection. (D) Bacterial colonization of the blood was enumerated at the indicated time points after infec-
tion. (E) Platelet numbers and (F) mean platelet volume (MPV) in the blood throughout infection. (G) Megakaryocytes (indicated by circles) in the spleen; 
H&E staining of frozen spleen sections at days 0 and 7 after infection. F, follicle. Scale bar: 100 μm. (H) Megakaryocytes per mm2 spleen. (I) Thrombo-
poietin concentration in the serum at the indicated time points after infection. Graphs show mean + SD. In all cases, data shown are representative of a 
minimum of 3 experiments, where n ≥ 4 mice in each group. Statistical significance was determined relative to day 7 after infection or to noninfected mice 
(D–F, H, and I). *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, 1-way ANOVA with Dunnett’s test (C–F and I) or Mann-Whitney sum of ranks test (H).
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ume in Ifng–/– mice were higher and lower, respectively, than those 
of infected WT animals and resembled those of the noninfected 
group (Figure 5, J and K). The markedly diminished leukocyte 
accumulation after infection in both TLR4- and IFN-γ-deficient 
mice establishes a critical role for both mediators in initiating the 
inflammatory cascade (Figure 5, L and M). The absence of inflam-
mation and thrombosis within the liver was independent of chang-
es in bacterial burdens, which were similar or higher than in WT 
mice in each case (Figure 5, N and O). This further supports the 
concept that bacterial infection is necessary to trigger the inflam-
matory and thrombotic cascades, but that additional mechanisms 
contribute to their maintenance.
Leukocytes isolated from day 7–infected Tlr4–/– livers cultured 
ex vivo produced considerably less IFN-γ than those cultured from 
WT mice (Figure 5P), demonstrating the necessity of TLR4 sig-
naling for optimal IFN-γ production during infection. Therefore, 
thrombosis is induced by inflammation mediated by TLR4 liga-
tion and IFN-γ production.
Podoplanin expression is elevated during infection. Given the 
temporal relationship of inflammation and thrombosis, we sought 
to identify a common pathway that could link inflammation to 
platelet activation. One protein that is associated with both activi-
ties is podoplanin. This molecule is upregulated on a variety of cell 
types during inflammation and mediates platelet activation via 
platelet-expressed CLEC-2 (30, 31). To identify a potential role 
led us to hypothesize that hepatic inflammation and thrombosis 
may be coregulated. If so, the link must be mediated through the 
innate immune system and not the adaptive system, since infect-
ed Rag1–/– mice, which lack mature B and T lymphocytes, exhibit a 
level of thrombosis similar to that of WT mice at day 7 after infec-
tion (Figure 4, G and H).
TLR4 and IFN-γ mediate inflammation and thrombus develop-
ment. A key sentinel molecule of the innate system that initiates 
inflammation in response to Gram-negative bacteria such as Sal-
monella is TLR4 (27). This receptor recognizes a range of bacte-
rial antigens, including LPS or endotoxin, and is expressed on 
multiple cell types, including Kupffer cells and monocytes (28). S. 
Typhimurium infection of Tlr4–/– mice for 7 days did not induce 
inflammatory foci and thrombus development (Figure 5, A–C). 
Furthermore, thrombocytopenia was not detected in these mice 
after infection (Figure 5, D and E). However, TLR4 stimulation 
after challenge of WT mice for 7 days with 20 μg of LPS alone 
was insufficient for thrombus development, demonstrating that 
thrombosis requires infection and is not merely associated with 
exposure to bacterial LPS (Figure 5F).
The absence of inflammation during early S. Typhimurium 
infection has been previously reported in IFN-γ–deficient mice 
(29). Paralleling an absence of inflammatory foci in Ifng–/– mice at 
day 7, there was also a lack of thrombus development in these mice 
(Figure 5, G–I). Moreover, platelet counts and mean platelet vol-
Figure 4. Thrombus development is not altered by common antiplatelet agents. (A) WT and Gpvi–/– mice were infected i.p. as above for 7 days. Thrombi 
were examined by H&E and (B) quantified by point counting of large vessels per tissue section. (C) WT mice were treated with clopidogrel (50 mg/kg i.v.) 
on day 3 after infection and daily (15 mg/kg i.v.) thereafter; thrombi were examined at day 7. (D) WT mice were treated with aspirin (30 mg/l in drinking 
water) on day 5 after infection and daily thereafter; thrombi were examined after 13 days and (E) were quantified by point counting as above. (F) WT mice 
were treated daily with heparin sodium (100 U/kg i.v.) from day 3 after infection; thrombi were examined at day 7 after infection. (G) WT and Rag1–/– mice 
were infected i.p as above; thrombi were examined after 7 days and (H) were quantified as above. All H&E was performed on frozen liver sections; all 
images are representative. Scale bars: 100 μm. Graphs show mean + SD. Experiments were performed at least twice with each group containing ≥ 4 mice.
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for podoplanin during S. Typhimurium infection, we monitored 
its expression in the liver by histology and flow cytometry. Podo-
planin expression was mainly restricted to lymphatic endothelial 
cells in noninfected mice (Figure 6A). Expression was dramatical-
ly increased in the liver within 24 hours of infection and remained 
elevated throughout infection (Figure 6A and Supplemental Fig-
ure 1; supplemental material available online with this article; 
doi:10.1172/JCI79070DS1). Vascular endothelial (CD31+) cells 
Figure 5. TLR4 and IFN-γ mediate inflammation and thrombus development. WT and Tlr4–/– mice were infected i.p. as above for 7 days. (A) Leukocyte infiltra-
tion of the liver was examined by IHC: CD11c (brown), F4/80 (blue). (B) Thrombus development was assessed by H&E staining and (C) was quantified by point 
counting of large vessels per tissue section. (D) Platelet numbers and (E) mean platelet volume were determined in the blood. (F) WT mice were treated with 20 
μg LPS, and thrombus development was examined in the liver after 7 days. WT and Ifng–/– mice were infected as above for 7 days, and (G) leukocyte infiltration 
of the liver was examined by IHC: CD11c (brown), F4/80 (blue). (H) Thrombus development was assessed by H&E staining and (I) was quantified as above. (J) 
Platelet numbers and (K) mean platelet volume were determined in the blood. Number of leukocytes isolated from the livers of infected WT and (L) Tlr4–/– or (M) 
Ifng–/– mice and (N and O) bacterial colonization of the liver were enumerated. (P) WT and Tlr4–/– mice were infected as above for 7 days, and leukocytes isolated 
from livers were cultured for 48 hours. Secreted IFN-γ was measured in culture supernatants by ELISA. Graphs show mean + SD. Experiments were performed at 
least twice, with each group containing ≥ 4 mice. Statistical significance was determined relative to WT mice. *P ≤ 0.05; **P ≤ 0.01; ***P ≤ 0.001, Mann-Whit-
ney sum of ranks test. ND, not detectable. All images are representative; black arrows indicate inflammatory lesions. Scale bars: 100 μm.
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did not express podoplanin before or during infection (Figure 6B). 
At day 7, podoplanin was highly expressed throughout the liver 
on leukocyte and nonleukocyte (CD45–) populations both within 
inflammatory foci and by cells that lie adjacent to the vascular 
endothelium (Figure 6C). These subendothelial podoplanin+ cells 
included CD248+ cells, indicating they could include pericytes 
or fibroblasts among other stromal populations, although not all 
CD248+ cells express podoplanin (Figure 6D).
Podoplanin is expressed by multiple macrophage populations in 
the liver during infection. Podoplanin expression has been previous-
ly reported on macrophages during inflammation, and so F4/80+ 
cells were further examined (24). Podoplanin is expressed by 
F4/80+ cells before and after infection (Figure 7A and Supplemen-
tal Figure 1A). F4/80+ cells isolated from the liver were catego-
rized according to expression of Ly6G, CD11c, CD11b, and Ly6C, 
and podoplanin expression of each population was measured by 
flow cytometry (Figure 7B and Supplemental Figure 2, A–C).
While the number of cells in most F4/80+ populations exam-
ined increased within 24 hours of infection (Figure 7C), the pro-
portion of cells expressing podoplanin was low, typically around 
5% (Figure 7D). By day 7 of infection, there was an increase in 
the numbers of cells in each of the 8 populations assessed (Figure 
7C) and the proportion of cells expressing podoplanin increased, 
most notably in the F4/80+Ly6GloCD11c+CD11bhiLy6Clo popula-
tion (population 2; Figure 7, C–D). Thus, podoplanin expression 
by F4/80+ subsets was widespread and heterogeneous by the time 
thrombosis was established in the liver (Figure 7E).
Increased numbers of podoplanin-expressing cells after infection 
is dependent on IFN-γ and TLR4. To determine whether there is 
a relationship between podoplanin expression and IFN-γ, we 
assessed IFN-γ expression by the podoplanin+ populations iden-
tified in Figure 7 using eYFP reporter mice (Figure 8A; represen-
tative FACS plots are shown in Supplemental Figure 3). Absolute 
numbers at all time points examined are shown in Supplemental 
Figure 4, A and B. At day 7 after infection, IFN-γ expression was 
found in F4/80+ cells that were CD11c+ and CD11c– and particu-
larly in those populations that were CD11b– (Figure 8B). Propor-
tionally, cells that were podoplanin+ were more likely to express 
IFN-γ (Figure 8B). In addition to F4/80+ cells, NK cells and simi-
lar numbers of invariant NKT (iNKT) cells were also found to 
express IFN-γ after infection (Figure 8C and data not shown). 
Nevertheless, thrombosis is not dependent upon NKT cells, as 
it was present to a similar extent in CD1d-deficient mice, which 
lack NKT cells (Figure 8D).
Figure 6. Podoplanin expression is elevated in the liver during infection. WT mice were infected i.p. as above for 7 days, and (A) podoplanin expression 
(green) was assessed in the liver alongside CD41 (red) and Hoechst (gray). (B) Podoplanin expression (blue) was examined with CD31 expression (green) in 
noninfected (top panel) and day 7–infected (bottom panel) sections; boxed areas are enlarged to the right-hand side. (C) Podoplanin (blue) expression by 
leukocytes was examined alongside CD41 (green), CD45.2 (red), and Hoechst (gray). (D) Podoplanin expression (blue) by stromal populations was examined 
alongside CD31 (green), CD248 (red), and Hoechst (gray). All images were obtained from frozen liver sections by fluorescent confocal microscopy. Scale 
bars: 100 μm unless indicated otherwise. LV, lymphatic vessel. Images are representative of ≥ 3 experiments with ≥ 4 mice in each group.
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Figure 7. Podoplanin is expressed by multiple macrophage populations in the liver during infection. WT mice were infected i.p. as above for 7 days, and 
(A) podoplanin expression (brown) was examined on frozen liver sections with F4/80 (blue). Scale bars: 100 μm. Arrows indicate inflammatory lesions. 
Podoplanin expression by macrophage populations was measured by flow cytometry on leukocytes isolated from livers. (B) The gating strategy used 
to phenotype macrophage-type cells (F4/80+Ly6Glo) into 8 populations, whereby population 1 represents CD11c+CD11bhiLy6Chi, population 2 represents 
CD11c+CD11bhiLy6Clo, population 3 represents CD11c+CD11bloLy6Chi, population 4 represents CD11c+CD11bloLy6Clo, population 5 represents CD11c–CD11bhiLy6Chi, 
population 6 represents CD11c–CD11bhiLy6Clo, population 7 represents CD11c–CD11bloLy6Chi, and population 8 represents CD11c–CD11bloLy6Clo. Representative 
FACS plots are shown in Supplemental Figure 2. (C) Absolute numbers of cells in each population. (D) Proportion and (E) absolute numbers of podoplanin+ 
cells in each population. Graphs show mean + SD from a representative experiment (1 of 4 repeat experiments), with each group containing ≥ 4 mice. Sta-
tistical significance was determined relative to noninfected mice. *P ≤ 0.05; ***P ≤ 0.001, 2-way ANOVA with Bonferroni’s post-test (C) or 1-way ANOVA 
with Dunnett’s test (E).
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inflammation and thrombosis and that the increase in its expres-
sion is absent in circumstances where thrombosis is also absent, 
we hypothesized that podoplanin upregulation provides the cru-
cial link between inflammation and thrombosis.
CLEC-2 expression on platelets is required for thrombus devel-
opment during infection. The interplay between podoplanin and 
CLEC-2 has been previously described during inflammation 
and has been shown to influence dendritic cell motility and the 
At day 7 after infection, the extent of podoplanin expression 
in IFN-γ– or TLR4-deficient livers was similar to that seen in 
noninfected mice; numbers of podoplanin-expressing cells were 
reduced relative to those in infected WT mice (Figure 8, E–G). 
Therefore, TLR4 ligation and IFN-γ production were required for 
podoplanin upregulation in addition to inflammatory foci develop-
ment and thrombosis. Considering that the temporal and spatial 
upregulation of podoplanin is consistent with a potential role in 
Figure 8. Increased numbers of podoplanin-expressing cells after infection are dependent on IFN-γ and TLR4. EYFP IFN-γ reporter mice were infected 
i.p. as above for 7 days, and IFN-γ production was examined by flow cytometry in leukocytes isolated from the liver. (A) Macrophage populations were clas-
sified according to the gating strategy outlined in Figure 7. IFN-γ–producing cells were identified by EYFP expression. Representative FACS plots are shown 
in Supplemental Figure 3. (B) The proportion (at day 7 after infection) of podoplanin+ (left panel) and podoplanin– (right panel) cells in populations 1–8 that 
are EYFP+. (C) Number of NK cells (CD3– NK1.1+) and IFN-γ+ NK cells per liver in noninfected and day 7–infected mice. (D) Cd1d–/– mice were infected as above, 
and thrombus development in the liver was examined by H&E at day 7. (E) Tlr4–/– and (F) Ifng–/– mice were infected as above for 7 days, and podoplanin 
expression (brown) was examined by IHC with F4/80 expression (blue). (G) Leukocytes were isolated from livers of WT and Tlr4–/– mice, and podoplanin 
expression was measured by flow cytometry. Absolute numbers of podoplanin+ cells from noninfected and day 7–infected mice. All experiments were per-
formed twice with ≥ 4 mice in each group at each time point. Data are shown as mean + SD. Statistical significance was determined relative to noninfected 
mice (C) or to WT mice (G). *P ≤ 0.05; **P ≤ 0.01, Mann-Whitney sum of ranks test. All images are representative and are from frozen liver sections. Scale 
bars: 100 μm. Arrows indicate inflammatory lesions.
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Figure 9. Thrombosis is dependent upon CLEC-2 expression on platelets. WT and Pf4-Cre Clec2fl/fl mice (lacking CLEC-2 expression on platelets) were 
infected i.p. as above for 7 days. (A) Thrombosis was examined on paraffin-embedded liver sections using H&E, and (B) vascular occlusion was quanti-
fied by point counting of large vessels per tissue section. (C) Absolute number of leukocytes isolated from the liver at day 7. (D) Leukocyte infiltration 
was examined by IHC: CD11c (brown), F4/80 (blue). Bacterial colonization of (E) liver, (F) blood, and (G) spleen at day 7. WT and Pf4-Cre Clec2fl/fl mice were 
infected as above for 35 days, and bacterial colonization of (H) the liver and (I) spleen were enumerated. (J) Podoplanin expression (brown) was examined 
in parenchymal (top panels) and vascular (bottom panels) regions of frozen liver sections by IHC with F4/80 (blue) at day 7 after infection. Leukocytes 
were isolated from the liver at day 7, and podoplanin expression was measured by flow cytometry. Leukocytes were classified by expression of F4/80 
and CD11c, as shown in Supplemental Figure 5. (K) Absolute numbers of podoplanin+ leukocyte populations. (L) Gpvi–/– Pf4-Cre Clec2fl/fl mice (lacking both 
CLEC-2 expression on platelets and constitutive GPVI expression) and (M) Vav1-iCre+ podoplaninfl/fl mice (lacking podoplanin expression on hematopoietic 
cells) and relevant littermate controls were infected as above, and thrombus development was examined on frozen liver sections by H&E at day 7 after 
infection. Data in L and M are each representative of 2 experiments where n ≥ 4 mice per group; remaining data and images are representative of experi-
ments performed at least 4 times using groups containing ≥ 4 mice. Graphs show mean + SD. Statistical significance was determined relative to WT 
mice. *P ≤ 0.05, Mann-Whitney sum of ranks test. Scale bars: 100 μm. Arrows indicate inflammatory lesions.
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thrombosis does not impede infection resolution in mice where 
inflammation is maintained. In addition, there was no feedback 
from the loss of CLEC-2 on podoplanin expression in the liver, 
indicating that the loss of thrombi is directly related to the inabil-
ity of podoplanin-expressing cells to interact with platelets (Figure 
9, J and K, and Supplemental Figure 5, A and B). Since occasional 
thrombi were seen in the Pf4-Cre Clec2fl/fl mice, it is possible that 
these could be mediated by GPVI. However, this was not the case, 
as residual thrombi were also present in infected Pf4-Cre Clec2fl/fl 
mice that were also deficient in GPVI (Figure 9L). Finally, mice 
with reduced podoplanin expression (Vav1-iCre+ podoplaninfl/fl 
mice) also had impaired thrombosis compared with Vav1-iCre– 
podoplaninfl/fl littermate controls (Figure 9M). Therefore, during 
S. Typhimurium infection, the podoplanin–CLEC-2 dyad controls 
thrombosis induction in a manner independent of GPVI.
Clodronate-sensitive cells mediate thrombus development. 
Since ligation of CLEC-2 on platelets is required for thrombus 
induction and F4/80+ cell populations constitute a substan-
tial source of podoplanin, it is possible that the lack of throm-
bosis in infected Tlr4–/– and Ifng–/– mice is due to insufficient 
podoplanin-expressing macrophage numbers in the liver. To 
test whether monocyte-lineage cells were therefore sufficient 
to drive platelet activation and thrombus formation, mice were 
treated before and during infection with clodronate liposomes 
maintenance of vascular integrity under thrombocytopenia (32, 
33). While platelet-expressed CLEC-2 has been implicated in the 
maintenance of vascular integrity at sites of inflammation, this 
role does not require platelet aggregation and thrombus formation 
(33). To investigate a role for CLEC-2 in S. Typhimurium–induced 
thrombosis, we studied Clec2fl/fl mice with a platelet-specific dele-
tion of CLEC-2 achieved using expression of Cre under a platelet 
factor 4 promoter (Pf4-Cre Clec2fl/fl). In these mice, thrombosis 
was markedly reduced at day 7 after infection, with most areas 
of the liver vasculature devoid of thrombus formation in most 
mice, demonstrating a critical role for platelet CLEC-2 (Figure 9, 
A and B). Importantly, this diminished thrombosis was not due to 
a lower level of inflammation or bacteremia, as leukocyte infiltra-
tion, inflammatory lesion development, and bacterial numbers 
were similar to those of infected littermate controls, indicating 
that other features of the infection were conserved despite the 
lack of CLEC-2 on platelets (Figure 9, C–E, and ref. 34). Similarly, 
both bacteremia and bacterial burden of other peripheral tissues 
such as the spleen were comparable to those of littermate con-
trols, further emphasizing the maintained control of infection in 
the absence of CLEC-2–activated platelets (Figure 9, F and G). 
Moreover, Pf4-Cre Clec2fl/fl mice were able to clear bacteria from 
the liver and spleen with kinetics similar to those of littermate con-
trols by day 35 after infection (Figure 9, H and I), indicating that 
Figure 10. Clodronate-sensitive cells mediate thrombus development. (A) WT mice were treated i.p. with PBS-loaded or clodronate-loaded liposomes for 
24 hours, and macrophage depletion was examined on frozen liver sections by IHC: F4/80 (blue). Images are representative of an experiment with 3 mice 
per group. (B–F) WT mice were treated with PBS- or clodronate-loaded liposomes 24 hours prior to infection with 5 × 105 CFU S. Typhimurium and every 48 
hours subsequently. Leukocytes were isolated from the liver at day 7 after infection, and macrophage populations were examined by flow cytometry. (B) 
Representative FACS plots and (C) absolute number/proportion of F4/80+ cells per liver at day 7 after infection. (D) Macrophage expression of podoplanin 
(brown) was examined by IHC in conjunction with F4/80 (blue). (E) Thrombosis was examined by H&E staining and (F) was quantified by point counting of 
large vessels per tissue section. Data in B–F are representative of 2 experiments where n = 5 in each group. Graphs show mean + SD; statistical significance 
was determined by comparison between PBS liposome– and clodronate liposome–treated mice. *P ≤ 0.05; ***P ≤ 0.001, Mann-Whitney sum of ranks test. 
All images were obtained from frozen liver sections. Scale bars: 100 μm. Arrows indicate inflammatory foci.
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Figure 11. Thrombi are anchored at sites of endothelial perturbation. WT mice were infected i.p. as above for 7 days. (A) Paraffin-embedded liver sections 
were examined at high magnification by H&E in regions adjacent to the portal vein (left panel) and within the parenchyma (right panel). (B–J) Frozen liver 
sections were examined by IHC/fluorescent confocal microscopy staining for (B) CD41 (blue), (C) CD31 (green), podoplanin (blue), and Hoechst (gray). Boxed 
regions are shown at a higher magnification in second, third, and fourth panels. (D) CD11c (brown), CD105 (blue). Left panel shows noninfected, middle 
panel shows day 7 infected, and right panel shows higher magnification of boxed region. (E) CD31 (green), TF (using antibody 1H1) (red), podoplanin (blue). 
Top panel shows noninfected, and bottom panel shows day 7 infected. (F) F4/80 (brown), TF (blue; using antibody AF3178). Left panel shows noninfected, 
and right panel shows day 7 infected; right image is an enlargement of the boxed region. (G) Podoplanin (green), F4/80 (red), and TF (blue; using antibody 
AF3178) (day 7 infected). (H) WT and Tlr4–/– mice and (I) WT and Pf4-Cre Clec2fl/fl mice were infected as above for 7 days, and liver sections were stained 
for (H) F4/80 (blue), TF (red; using antibody 1H1), (I) F4/80 (green), TF (red; using antibody 1H1), podoplanin (blue), and (J) fibrin (green), CD41 (red) (WT, 
day 7 infected). Images in A–G, I, and J are representative of a minimum of 3 experiments, where n ≥ 4 mice per group. Images in H are representative of 2 
experiments with ≥ 4 mice per group. Scale bars: 100 μm, unless indicated. Yellow circles indicate areas of compromised endothelial integrity.
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The identification of TF within thrombi suggests that the 
coagulation cascade may also contribute to the propagation of this 
pathway of thrombosis. Indeed, CD41+ platelet thrombi costained 
with anti-fibrin, indicating that thrombi were rich in fibrin, the 
end product of the coagulation cascade (Figure 11J). In addition, 
thrombi also stained positive for vWF, as did CD31+ vascular endo-
thelial cells (Supplemental Figure 6). This suggests that, although 
the induction of the thrombotic pathway is through CLEC-2 acti-
vation of platelets, the downstream processes share similarities 
with classical pathways of thrombosis.
Discussion
This study reports a mechanism that links infection, inflamma-
tion, and thrombosis. Based on our findings, we propose a model 
as to how systemic S. Typhimurium infection induces thrombo-
sis. After infection, there is a differential capacity of the bacte-
rium to colonize solid organs, such as the liver, or to persist in the 
blood. The bacteria in the liver cause a TLR4- and IFN-γ–depen-
dent accumulation of podoplanin-expressing monocyte-lineage 
cells. As a consequence of the combination of bacteremia, infec-
tion of the liver, inflammation, and cellular migration into the 
liver, the vascular endothelium becomes damaged, exposing 
platelets to these podoplanin-expressing cells (both of monocyt-
ic lineage and podoplanin+ cells of other CD45– lineages). This 
combination of podoplanin sources results in platelet activation 
via CLEC-2. In this process, infection is the triggering event for 
the development of inflammation that leads to the thrombotic 
response, with the maintenance of the response being indepen-
dent of continuing infection and instead paralleling the regula-
tion of inflammation. Nevertheless, it is unclear whether an indi-
vidual thrombus persists throughout the infection or whether 
there were cycles of thrombus formation and collapse. Elucidat-
ing this will be highly relevant for understanding how to inter-
vene in this process.
While the importance of macrophages and IFN-γ in the 
immune response to S. Typhimurium is well established, particu-
larly with regard to bacterial clearance (36, 37), this TLR4-depen-
dent inflammatory cascade has not been previously associated 
with altered podoplanin expression. Similarly, while podoplanin 
expression by macrophages has been described during inflamma-
tion (24) and has been putatively associated with TLR4 signaling 
in vitro (38), here, we provide in vivo evidence linking podoplanin 
expression to TLR4/IFN-γ–dependent inflammation. Further-
more, we demonstrate a functional application for podoplanin 
upregulation in CLEC-2–dependent thrombosis. Considering the 
increased numbers of CD248+ cells previously shown in the spleen 
following Salmonella infection (39), here, we demonstrate by clo-
dronate depletion that podoplanin expression by nonmacrophage 
populations is insufficient for thrombus development. Further 
investigation will be required to determine whether TF, which is 
also seen, actively contributes to this process.
The benefits of current antiplatelet medications, such as hepa-
rin, to treat thrombosis associated with infection are unclear (40). 
Indeed, we have shown that S. Typhimurium–mediated throm-
bosis in the liver is not altered by pretreatment with the orally 
available antiplatelet drugs aspirin and clopidogrel, which inhibit 
thromboxane formation and block the platelet P2Y12 ADP recep-
or PBS liposomes. Clodronate treatment prior to infection 
reduced F4/80+ cell numbers in the liver (Figure 10A). After 
infection, some increase in F4/80+ cells was observed; however, 
F4/80+ cell numbers and proportions were significantly lower 
at day 7 after infection relative to PBS liposome treatment (Fig-
ure 10, B and C). Reduced F4/80+ cell numbers in the liver were 
paralleled by reduced podoplanin expression on tissue sections 
after infection and by the abrogation of thrombus development 
(Figure 10, D–F). Therefore, clodronate-sensitive monocyte- 
lineage cells regulate the induction of thrombosis through a 
podoplanin–CLEC-2–dependent mechanism.
Endothelial damage exposes podoplanin, facilitating CLEC-2–
dependent platelet activation. Having demonstrated that platelet 
activation in this model is CLEC-2 dependent and that podoplanin 
expression by macrophage subsets is required to facilitate this acti-
vation, we wanted to identify where this platelet-podoplanin inter-
action occurs. Considering podoplanin is expressed by Kupffer 
cells (among other macrophage subsets) that are primarily local-
ized to the sinusoids, it seemed plausible that platelet activation 
may occur within the parenchyma. However, thrombi were not 
detected within the sinusoids, either in the presence or absence of 
infection, suggesting that platelet exposure to Kupffer cells during 
normal perfusion of the liver is not sufficient for thrombus induc-
tion (Figure 11A and data not shown). Instead, we saw regions 
adjacent to the vascular endothelium of the portal vein where 
platelets appeared to “anchor” the thrombi to the side of the ves-
sel wall (Figure 11B). In these regions, the platelets formed mini- 
protrusions into the parenchyma, suggesting platelets become 
activated at points where there is perturbation of the integrity of 
the portal vein endothelium. At such points, there were interrup-
tions in the CD31+ vascular endothelium (Figure 11C). This dis-
continuous endothelial staining was also observed when other 
markers, such as CD105, were used and suggests this is not simply 
reflecting some change in CD31 expression (Figure 11D).
Expression of tissue factor (TF), a key component of coagula-
tion, by macrophages has been previously shown to be enhanced 
in response to TLR4 stimulation by LPS (35). While TF is not 
readily detected in noninfected mice, at day 7 after infection, TF 
staining could be seen in perivascular sites, although it was not 
expressed by CD31+ vascular endothelium (Figure 11, E–G). After 
infection, TF was detected on F4/80+ and F4/80– cells; how-
ever, only a small proportion of F4/80+ cells expressed TF (Fig-
ure 11F). Occasionally, TF was observed at the same anatomical 
sites as podoplanin and could sometimes be found on the same 
cells; however, TF was not expressed by podoplanin+ lymphatic 
endothelial cells (Figure 11, E and G). TF staining could be asso-
ciated with thrombi themselves, although this was not observed 
on all thrombi and the staining was localized to the periphery of 
thrombi (Figure 11, F and G). An absence of thrombosis in TLR4- 
deficient/macrophage-depleted animals could also reflect a 
reduction in TF present. In Tlr4–/– mice, TF expression was 
reduced, but still present and detectable on F4/80+ cells (Fig-
ure 11H). This suggests that the absence of thrombosis in TLR4-
deficient mice is unlikely to be due to an absence of TF. Similarly, 
TF was detected on F4/80+ cells in Pf4-Cre Clec2fl/fl mice at day 7 
after infection, further suggesting that TF expression is not suf-
ficient for thrombus development (Figure 11I).
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thrombosis is likely to be common; one study found 3 of 5 patients 
who died from typhoid had evidence of disseminated intravascu-
lar coagulation (50, 51).
There are multiple potential scenarios as to how thrombosis 
may contribute to the outcome of infection. Thrombosis may help 
restrict bacterial dissemination by limiting bacterial trafficking 
through the blood. Alternatively, if thrombi exceed a certain size, 
they may become harmful. An exaggerated thrombotic response 
may result in the development of unstable thrombi; it is possible 
to envisage that such thrombi may break up (embolize), leading to 
additional complications, such as cerebral infarction or pulmonary 
embolism. Whether this occurs is likely to reflect a combination of 
factors that include the extent of thrombosis within an individual 
site and the stability of an individual thrombus. Central to under-
standing the role of thrombosis in infection will be understanding 
the spectrum of manifestations it can take in an individual host.
Our ability to interrogate this in depth using the geneti-
cally altered mice in this study is complicated by the nature of 
the murine Salmonella infection model, where susceptibility is 
strongly influenced by the genetic background of the mouse strain 
used (52). In hypersusceptible mice, such as those on a C57BL6/J 
or BALB/c background, use of an attenuated Salmonella strain 
enables the infection to be followed for many weeks. The com-
promise associated with using this model is that the extent of the 
infection is not as severe as that observed using resistant strains of 
mice with fully virulent strains of bacteria. Evidence from other 
descriptive studies shows that when mice are infected with more 
virulent strains of Salmonella, thrombi can form in other sites such 
as the spleen, and so thrombosis is not necessarily restricted to 
the liver (9). Further studies are needed to identify whether the 
mechanism for thrombosis identified here is applicable to other 
systemic infections such as those caused by Escherichia coli, which 
can cause hemolytic uremia syndrome in certain populations (53).
It is also noteworthy that, while inflammation and thrombo-
sis were abolished in TLR4- and IFN-γ–deficient mice and in mice 
treated with clodronate, a residual level of thrombosis was seen 
in CLEC-2–deficient mice. A similar level of residual thrombus 
formation was seen in mice double deficient for CLEC-2 and the 
collagen receptor GPVI, indicating that this residual response is 
not mediated by this classical mechanism of platelet activation. 
This may suggest that additional minor mechanisms that were 
triggered by the TLR4-mediated events early after infection were 
also involved, but it may simply reflect CLEC-2 engagement being 
the final step in this cascade, and so some infrequent thrombosis 
could still be triggered.
In this model, thrombosis is mirrored by decreased circulating 
platelets; thus, it is plausible that this thrombocytopenia is simply 
a reflection of platelet consumption, a concept supported by the 
lack of thrombocytopenia in TLR4- and IFN-γ–deficient mice. 
However, considering that platelet numbers drop within 24 hours, 
several days before thrombi appear, it is probable that other mech-
anisms also contribute to thrombocytopenia. One possible way is 
via platelet development, which may be affected by the dramatic 
effect of this infection on bone marrow progenitor populations 
(54). Interestingly, thrombocytopenia is often observed after Sal-
monella infections in mice and humans and has been observed in 
humans infected with an attenuated strain of Salmonella given as a 
tor, respectively (Figure 4). Moreover, seeing as liver injury during 
infection is relatively mild (Figure 2, F–J), it is unlikely to compro-
mise the conversion of clopidogrel to its active metabolite.
The identification of CLEC-2 as a critical player in this path-
way opens the possibility of the development of a new class of 
antithrombotic agent with minimal, if any, effect on hemostasis 
or risk of increased bleeding. An important consideration in this 
context is the maintained separation of lymphatic/blood vascula-
ture in the adult, a process that has been argued to be reliant on 
the interaction between CLEC-2 and podoplanin (41). Therefore, 
the possible compromised integrity of de novo angiogenesis dur-
ing infection must be accounted for if this pathway is to be manip-
ulated therapeutically, although any such intervention would 
likely only be used for short periods. The only known endogenous 
ligand for CLEC-2 is podoplanin, which is absent in the vascula-
ture and at sites of acute tissue injury. This is consistent with the 
observation that tail bleeding times in mice, the most widely used 
model of hemostasis, have been shown to be minimally altered 
in mice deficient in CLEC-2 (42–44). A role for CLEC-2 in throm-
bosis has been observed in some but not all studies, notably in 
association with GPVI (44).
A key point to examine is whether this mechanism of infec-
tion- and inflammation-driven thrombosis is beneficial to the host 
in that it may provide a pathway of bacterial capture and removal, 
as recently reviewed (14). However, we did not find evidence for 
a contribution of thrombosis to limiting bacteremia early during 
infection in our model, where thrombosis persisted for weeks 
after bacteremia was absent and tissue bacterial numbers were 
resolving. There are a number of potential reasons for this, some 
of which may relate to the model and some to the nature of the 
infection. Perhaps central to the latter point is the natural history 
of this infection in humans, which is characterized by high bacte-
rial numbers in tissues such as the spleen, liver, and bone marrow, 
but low numbers in the blood (3). In a recent controlled study of 
typhoid infection in human volunteers, bacteremia occurred in 
the majority of cases, but subjects had less than 2 bacteria per ml 
of blood (45). Such a modest bacteremia is also a feature of inva-
sive nontyphoidal Salmonella infections. Even in humans who 
have additional complications, such as HIV coinfection, bacterial 
densities were typically less than 10 bacteria per ml of blood (46), 
and yet it is culture-confirmed bacteremia that is a leading prog-
nostic indicator for poor outcome.
This is a substantially different presentation from those of 
many more “classical” infections associated with thrombosis, 
such as pneumococcal or staphylococcal infections, where bac-
terial burdens can reach many magnitudes of order higher (47, 
48). One interpretation of this is that there are multiple potential 
mechanisms that can be involved in inducing thrombosis after 
infection, some of which may be influenced by the predominant 
distribution of bacteria between the blood and other sites. The 
low bacteremia associated with invasive Salmonella infections 
influence the potential of thrombosis to be of benefit to the host. 
It is possible that thrombosis/platelet activation has additional 
effects on the host that are independent of controlling bacte-
rial numbers, such as maintaining vessel integrity after damage. 
Platelets contain multiple immunomodulatory factors that could 
be released during thrombus generation (49). Nevertheless, 
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(Plavix) tablets (75 mg) were ground to a fine powder and dissolved (as 
an emulsion) in 0.5% methylcellulose solution. Mice were treated (50 
mg/kg) i.v. on day 3 after infection, and treatment (15 mg/kg i.v.) was 
then administered daily on days 4, 5, and 6 after infection. Heparin 
sodium (100 U/kg) was administered i.v. on day 3 after infection, and 
treatment (100 U/kg i.v.) was maintained daily for 3 days.
Immunohistology and confocal microscopy. Tissues were snap- 
frozen or fixed in 4% formaldehyde immediately upon removal. Par-
affin-embedded tissue sections were stained by H&E. Frozen tissue 
sections were stained by IHC to detect CD3 (145-2C11, BD Biosciences 
— Pharmingen), F4/80 (Cl:A3:1, AbD Serotec), CD11c (N418, AbD 
Serotec), Ly6C (AL-21, BD Biosciences), Ly6G (RB6-8C5, eBioscience), 
CD105 (MJ7/18, BD Biosciences), TF (polyclonal; AF3178, R&D Sys-
tems), and podoplanin (eBio8.1.1, eBioscience), as described previously 
(73). IHC was performed in Tris buffer (pH 7.6). Primary and second-
ary antibodies were added for 60 and 45 minutes, respectively, at room 
temperature. Biotin- or horseradish peroxidase–conjugated secondary 
antibodies were developed using alkaline phosphatase (ABComplex, 
Vector Laboratories) and levamisole with napthol AS-MX phosphate 
and Fast Blue BB salt or 3,3′-diaminobenzidine tetrahydrochloride, 
respectively. Slides were mounted in glycerol and images acquired at 
×20 magnification using a Leica CTR6000 microscope (Leica) with a 
QImaging MicroPublisher 5.0 RTV camera in conjunction with ImageJ 
(http://imagej.nih.gov/ij/) and QCapture software. Low magnification 
images were acquired by a Carl Zeiss AxioScan.Z1 Slide Scanner using 
a 3CCD color 2MP Hitachi 1200 × 1600 HV-F202SCL camera. Images 
were analyzed using Zen blue (edition 2012) slide scan software.
Fluorescent confocal microscopy was performed on frozen liver 
sections stained with the following: CD41 (clone MWReg30), CD45.2 
(clone 104), CD248 (a gift from Clare Isacke, Institute of Cancer 
Research, London, United Kingdom), CD31 (clone 390) vWF (clone 
H-300), mouse anti-human fibrin (clone 59D8) (a gift from Rodney 
Camire, Children’s Hospital of Philadelphia, Philadelphia, Penn-
sylvania, USA) (74), and podoplanin (clone eBio8.1.1) as previously 
described (73). TF was detected using either a goat anti-mouse anti-
body (AF3178 from R&D Systems) or a rat anti-mouse monoclonal 
antibody (1H1) (75). Staining was performed in PBS plus 1% FCS. Sec-
tions were incubated with primary and secondary antibodies for 90 
and 45 minutes, respectively, at room temperature in the dark. Nuclei 
were detected by Hoechst 33342 (10 μg/ml for 2 minutes at room 
temperature). Slides were mounted using Prolong Gold Anti-Fade 
Reagent (Invitrogen), and images were taken using a ×63 magnifica-
tion objective on a LSM510 laser scanning confocal microscope with a 
Zeiss AxioVert 100M in conjunction with Zeiss LSM image software.
Histological quantification. The proportion of liver area occupied 
by inflammatory lesions was quantified by point counting (68). The 
proportion of grid intercepts on lesions was calculated from the total 
intercepts covering the area counted (60 grids per tissue, representa-
tive of the entire tissue section). The percentage of vessel occlusion 
was measured by the proportion of grid intercepts on thrombi in large 
vessels out of total grid intercepts on large vessels. For standardiza-
tion, only the largest vessels (greater than 50 intercepts) were includ-
ed, and livers were sectioned to similar positions in each tissue.
Flow cytometry. Leukocytes were isolated from livers by collagenase 
digestion and gradient centrifugation as described elsewhere (76–78). 
Briefly, livers were mechanically disrupted and immersed in collage-
nase D (1 μg/ml) (20 minutes, 37°C with agitation [180 rpm]); reactions 
treatment against cancer (9, 55, 56). Therefore, despite the effects 
that molecules such as TLR4 have on influencing platelet numbers 
after LPS challenge (57), the thrombocytopenia observed during 
infection is likely to be due to a combination of factors.
The present results may provide a mechanism to explain 
some of the deaths observed after invasive nontyphoidal Salmo-
nella infections in infants in sub-Saharan Africa. In these cases, 
when infants present at clinic with bacteremia, up to 20% will die 
within 24 hours, despite the modest bacteremia associated with 
systemic nontyphoidal Salmonella infections (58–60). If so, it 
would suggest that understanding immunopathology after infec-
tion should be as important a focus of research for control of the 
sequelae of infection as trying to identify how to restrict bacterial 
numbers through antimicrobial treatment. For instance, in this 
study, we observed reduced cellular infiltration and negligible 
thrombus development in Ifng–/– mice, despite there being 10-fold 
higher bacterial numbers at day 7.
The pathway that we describe here may also play a role in other 
conditions associated with inflammation and thrombosis, such as 
secondary hemophagocytic lymphohistiocytosis, a life-threaten-
ing condition associated with hyperinflammation due to dysregu-
lated proliferation of lymphocytes and macrophages (61). If a role 
for podoplanin and CLEC-2 emerges in these clinical conditions, it 
will highlight this interaction as a key target for therapeutic inter-
vention. Understanding when and how podoplanin and CLEC-2 
are induced and interact will provide numerous new opportunities 
to therapeutically intervene without the risk of increased bleeding 
that is associated with other forms of antithrombotic therapy.
Methods
Mice. C57BL/6J mice and BALB/c mice (6 to 8 weeks) were obtained 
from Harlan OLAC Ltd. or from in-house colonies, respectively. Tlr4–/– 
mice were from Oriental Bioservice. Ifng–/– mice, Rag1–/– mice, Ifng-
eYFP (GREAT) reporter mice, Vav1-iCre+ podoplaninfl/fl mice (obtained 
from Jackson Laboratories), and Pf4-Cre Clec2fl/fl mice are described 
elsewhere (41, 62–65). Gpvi–/– mice (66) were a gift from Jerry Ware 
(University of Arkansas, Fayetteville, Arkansas, USA). Cd1d–/– mice 
were originally from Luc Van Kaer (Vanderbilt University Medical 
Centre, Nashville, Tennessee, USA) (67). Gpvi–/– Pf4-Cre Clec2fl/fl mice 
were generated by breeding of Gpvi–/– Pf4-Cre Clec2fl/+ with Gpvi–/– 
Clec2fl/fl mice in-house at the Biomedical Services Unit (BMSU), Uni-
versity of Birmingham. All strains of genetically altered mice were on 
a C57BL/6J background with the exception of Tlr4–/– mice, which were 
on a BALB/c background. Control mice were matched by genetic back-
ground, age, and sex. All mice were housed at the BMSU.
Bacteria and infection protocol. Mice were infected i.p. or i.v. with 5 × 
105 attenuated Salmonella Typhimurium SL3261 as described previous-
ly (68). Noninfected or mock PBS–immunized mice were used as con-
trols. Tissues were removed at the indicated time points after infection.
Clodronate treatment. Treatment with clodronate liposomes was 
performed as described elsewhere (69–72). Mice were treated i.p with 
200 μl clodronate liposomes or PBS liposomes 24 hours before S. 
Typhimurium infection (i.p.) and every 2 to 3 days subsequently.
Antiplatelet treatments. WT mice were infected as described 
above. Aspirin (30 mg/l, freshly prepared every other day) was admin-
istered daily via drinking water beginning on day 5 after infection, 
and treatment was maintained constantly until day 13. Clopidogrel 
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Online supplemental material. Additional examples of flow cytom-
etry gating strategies used, representative FACS plots, and further his-
tological images are shown in Supplemental Figures 1–6.
Statistics. Statistical significance was determined using the 
2-tailed Mann-Whitney nonparametric sum of ranks test, 1-way 
ANOVA with the Dunnett’s test, or 2-way ANOVA with Bonferroni’s 
post-test. All P values were calculated using GraphPad Prism version 
4.0 and were interpreted as significant at P ≤ 0.05.
Study approval. All animal procedures were carried out in strict 
accordance with local ethical approval from the University of Birming-
ham and the UK Home Office license (project license 30/2850) as cov-
ered by the Animals (Scientific Procedures) Act 1986.
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were stopped with 0.5 mM EDTA. Livers were homogenized through a 
70-μm nylon cell strainer in RPMI supplemented with 2% FBS and 5 mM 
EDTA. Leukocytes were isolated using a Ficoll Paque PLUS (GE Health-
care) gradient at 375 g for 20 minutes without brake. Cells were collect-
ed from the interface layer, and CD32/FcγIII and CD16/FcγII receptors 
were blocked prior to staining with the following antibodies: CD45 (30-
F11), F4/80 (BM8), CD11c (HL3), CD11b (M1/70), Ly6C (HK1.4), Ly6G 
(RB6-8C5), NK1.1 (PK136), and podoplanin (eBio8.1.1). IgG isotype con-
trol PE antibody was used in conjunction with anti-podoplanin staining. 
All antibodies used were conjugated to either FITC, PE, Per-CP-Cy5.5, 
PE-Cy5, APC, Pacific blue, PE-Cy7, APC, APC-Cy7, biotin, or PE–Texas 
red; biotinylated antibodies were detected using streptavidin-APC-Cy7. 
All antibodies were obtained from eBioscience; CD11c-PE-Cy7 was 
obtained from BD Biosciences. Cells were fixed in 0.1% paraformalde-
hyde and were acquired using a CyAn FACS Analyzer (Dako).
Cytokine ELISA. Leukocytes from livers were cultured for 48 
hours in RPMI supplemented with 10% FCS and 1% penicillin/strep-
tomycin at 37°C with 5% CO2. Supernatants were collected, and 
IFN-γ concentration was determined by ELISA (Ready-Set-Go Kit, 
eBioscience) according to the manufacturer’s instructions. Briefly, 
wells were coated overnight at 4°C with anti–IFN-γ capture antibody 
before samples/standards were added overnight at 4°C. Biotinylated 
anti–IFN-γ detection antibody was added for 1 hour, and IFN-γ signal 
was detected using avidin-HRP and 3,3′,5,5′-tetramethylbenzidine 
solution. The reaction was stopped with 1 M H3PO4, and absorbance 
at ODλ450 nm was determined using an EMax microplate spectropho-
tometer (Molecular Devices).
Thrombopoietin serum ELISA. Serum was isolated from whole 
blood (centrifugation at 6000 g for 15 minutes) and was stored at 
–20°C. Thrombopoietin concentration was determined using the 
Thrombopoietin Quantikine ELISA Kit (R&D Systems) according to 
the manufacturer’s instructions.
Biochemical liver injury assays. Serum was isolated from whole 
blood, and liver-specific enzymes were detected in conjunction with 
the Biochemistry Department at the Birmingham Women’s Hospital, 
Birmingham, United Kingdom.
Whole blood analysis. Whole blood was obtained by cardiac punc-
ture into EDTA-coated (5 mM) plastic tubes, and cellular parameters 
were quantitatively measured using an automated ABX Pentra 60 
Hematology Analyzer (Horiba ABX Diagnostics), according to the 
manufacturer’s instructions.
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